Journal of the American College of Surgeons
Volume 205, Issue 1 , Pages 78-88 , July 2007

Temporal Expression of the Transforming Growth Factor-Beta Pathway in the Rabbit Ear Model of Wound Healing and Scarring

Received 15 November 2006 ,Revised 23 February 2007 ,Accepted 5 March 2007.

References 

  1. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995;108:985–1002
  2. Houghton PE, Keefer KA, Krummel TM. The role of transforming growth factor-β in the conversion from “scarless” healing to healing with scar formation. Wound Rep Reg. 1995;3:229–236
  3. McCallion RL, Ferguson MW. Fetal wound healing and the development of antiscarring therapies for adult wound healing. In:  Clark RAF editors. The molecular biology of wound repair. New York: Plenum Press; 1996;
  4. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004;18:816–827
  5. Lu L, Saulis AS, Liu WR, et al. The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J Am Coll Surg. 2005;201:391–397
  6. Derynck R, Feng XH. TGF-beta receptor signaling. Biochim Biophys Acta. 1997;1333:F105–F150
  7. Varga J. Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum. 2002;46:1703–1713
  8. Liu W, Chua C, Wu X, et al. Inhibiting scar formation in rat wounds by adenovirus-mediated overexpression of truncated TGF-beta receptor II. Plast Reconstr Surg. 2005;115:860–870
  9. Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralizing antibody to transforming growth factor beta. Lancet. 1992;339:213–214
  10. Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum. 2001;44:731–734
  11. Yamamoto T, Takagawa S, Katayama I, Nishioka K. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol. 1999;92:6–13
  12. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163:5693–5699
  13. Hill C, Flyvbjerg A, Rasch R, et al. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol. 2001;170:647–651
  14. Reid RR, Roy NK, Mogford JE, et al. Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-beta receptor II. J Plast Reconstr Aesthet Surg. 2007;60:64–72
  15. Wang Q, Wang Y, Hyde DM, et al. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax. 1999;54:805–812
  16. Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest. 1999;104:5–11
  17. Terada Y, Hanada S, Nakao A, et al. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int. 2002;61:94–98
  18. Inagaki Y, Truter S, Ramirez F. Transforming growth factor-beta stimulates alpha 2(I) collagen gene expression through a cis-acting element that contains an Sp1-binding site. J Biol Chem. 1994;269:14828–14834
  19. Chung KY, Agarwal A, Uitto J, Mauviel A. An AP-1 binding sequence is essential for regulation of the human alpha2 (I) collagen (COL1A2) promoter activity by transforming growth factor-beta. J Biol Chem. 1996;271:3272–3278
  20. Chen SJ, Yuan W, Mori Y, et al. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol. 1999;112:49–57
  21. Mori Y, Chen SJ, Varga J. Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-beta. Exp Cell Res. 2000;258:374–383
  22. Morris DE, Wu L, Zhao LL, et al. Acute and chronic animal models for excessive dermal scarring: quantitative studies. Plast Reconstr Surg. 1997;100:674–681
  23. Saulis AS, Mogford JH, Mustoe TA. Effect of Mederma on hypertrophic scarring in the rabbit ear model. Plast Reconstr Surg. 2002;110:177–183
  24. Kim I, Mogford JE, Gunzman V, Mustoe TA. Inhibition of prolyl 4-hydroxylase reduces scar hypertrophy in a rabbit model of cutaneous scarring. Wound Repair Regen. 2003;11:368–372
  25. Reid RR, Mogford JE, Butt R, et al. Inhibition of procollagen C-proteinase reduces scar hypertrophy in a rabbit model of cutaneous scarring. Wound Repair Regen. 2006;14:138–141
  26. Marcus JR, Tyrone JW, Bonomo S, et al. Cellular mechanisms for diminished scarring with aging. Plast Reconstr Surg. 2000;105:1591–1599
  27. Wu L, Siddiqui A, Morris DE, et al. Transforming growth factor beta 3 (TGF beta 3) accelerates wound healing without alteration of scar prominence (Histologic and competitive reverse-transcription-polymerase chain reaction studies). Arch Surg. 1997;132:753–760
  28. Sisco M, Kryger Z, Jia S, et al. Antisense oligonucleotides against transforming growth factor-beta delay wound healing in a rabbit ear model. J Am Coll Surg. 2005;201:S60
  29. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature. 2003;425:577–584

 Competing Interests Declared: None.This work was supported by NIH grant no GM063825.

PII: S1072-7515(07)00384-5

doi: 10.1016/j.jamcollsurg.2007.03.001

Journal of the American College of Surgeons
Volume 205, Issue 1 , Pages 78-88 , July 2007

Article Tools

* Image Usage & Resolution